A detailed history of Two Sigma Investments, LP transactions in Evolus, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 40,700 shares of EOLS stock, worth $692,714. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,700
Previous 132,751 69.34%
Holding current value
$692,714
Previous $1.86 Million 76.26%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.45 - $13.76 $961,932 - $1.27 Million
-92,051 Reduced 69.34%
40,700 $441,000
Q1 2024

May 15, 2024

BUY
$9.99 - $14.91 $62,907 - $93,888
6,297 Added 4.98%
132,751 $1.86 Million
Q4 2023

Feb 14, 2024

BUY
$7.6 - $10.53 $394,303 - $546,317
51,882 Added 69.57%
126,454 $1.33 Million
Q3 2023

Nov 14, 2023

BUY
$7.15 - $10.2 $290,089 - $413,834
40,572 Added 119.33%
74,572 $681,000
Q2 2023

Aug 14, 2023

BUY
$7.23 - $10.52 $10,845 - $15,780
1,500 Added 4.62%
34,000 $247,000
Q1 2023

May 15, 2023

BUY
$7.81 - $11.05 $108,121 - $152,976
13,844 Added 74.21%
32,500 $274,000
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.95 $121,637 - $166,971
18,656 New
18,656 $140,000
Q2 2022

Aug 15, 2022

BUY
$10.22 - $13.94 $191,614 - $261,361
18,749 Added 145.66%
31,621 $367,000
Q1 2022

May 16, 2022

BUY
$5.22 - $11.78 $67,191 - $151,632
12,872 New
12,872 $144,000
Q4 2021

Feb 14, 2022

SELL
$5.37 - $8.38 $507,572 - $792,077
-94,520 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$7.36 - $13.67 $884,083 - $1.64 Million
-120,120 Reduced 55.96%
94,520 $720,000
Q2 2021

Aug 16, 2021

BUY
$8.42 - $13.96 $1.81 Million - $3 Million
214,640 New
214,640 $2.72 Million
Q1 2019

May 15, 2019

SELL
$12.43 - $28.91 $554,092 - $1.29 Million
-44,577 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$10.57 - $19.29 $471,178 - $859,890
44,577 New
44,577 $530,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $955M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.